Temporal relationship between renal cyst development, hypertension and cardiac hypertrophy in a new rat model of autosomal recessive polycystic kidney disease

Kidney and Blood Pressure Research

Volumn 30, Issue 3, 2007, Pages 129-144

  Phillips, Jacqueline K ^a   Hopwood, Deborah ^b   Loxley, Rhonda A ^a   Ghatora, Kamaljit ^d   Coombes, Jason D ^d   Tan, Ying Sin ^c   Harrison, Joanne L ^a   McKitrick, Douglas J ^c   Holobotvskyy, Vasyl ^c   Arnolda, Leonard F ^c   Rangan, Gopala K ^d  

^a MURDOCH UNIVERSITY   (Australia)

^b Animal Resources Centre   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d WESTMEAD HOSPITAL   (Australia)

Author keywords

Autosomal recessive polycystic kidney disease; Cystogenesis; Hypertension; Immunohistochemistry; Left ventricular hypertrophy; Renin angiotensin aldosterone system; Sympathetic nervous system

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ANGIOTENSIN II; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GLOBULIN; HEXAMETHONIUM; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN; RENIN;

ADRENERGIC SYSTEM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOSOMAL RECESSIVE INHERITANCE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE MODEL; FEMALE; HEART HYPERTROPHY; HEART LEFT VENTRICLE HYPERTROPHY; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY COLLECTING TUBULE; KIDNEY CYST; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; MALE; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; CREATININE; DISEASE MODELS, ANIMAL; FEMALE; HYPERTENSION, RENAL; HYPERTROPHY, LEFT VENTRICULAR; IMMUNOHISTOCHEMISTRY; KIDNEY CORTEX; KIDNEY MEDULLA; KIDNEY TUBULES, DISTAL; KIDNEY TUBULES, PROXIMAL; LIVER; MALE; MYOCARDIUM; POLYCYSTIC KIDNEY, AUTOSOMAL RECESSIVE; PREDICTIVE VALUE OF TESTS; RATS; RATS, INBRED LEW; RATS, MUTANT STRAINS; RENIN-ANGIOTENSIN SYSTEM; SYMPATHETIC NERVOUS SYSTEM; SYMPATHOLYTICS; TIME FACTORS; UREA;

EID: 34250875018     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000101828     Document Type: Article

References (66)

1. Gabow PA, Chapman AB, Johnson AM: Renal structure and hypertension in autosomal dominant polycystic kidney disease. Kidney Int 1990;38:1177-1180.
2. Capisonda R, Phan V, Traubuci J, Daneman A, Balfe JW, Guay-Woodford LM: Autosomal recessive polycystic kidney disease: outcomes from a single-center experience. Pediatr Nephrol 2003;18:119-126.
3. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ: Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 2001;12:2427-2433.
4. Neumann J, Ligtenberg G, Klein IH, Blankestijn PJ: Pathogenesis and treatment of hypertension in polycystic kidney disease. Curr Opin Nephrol Hypertens 2002;11:517-521.
5. Wang D, Strandgaard S: The pathogenesis of hypertension in autosomal dominant polycystic kidney disease. J Hypertens 1997;15:925-933.
6. Ecder T, Schrier RW: Hypertension and left ventricular hypertrophy in autosomal dominant polycystic kidney disease. Expert Rev Cardiovasc Ther 2004;2:369-374.
7. Bardaji A, Martinez-Vea A, Valero A, Gutierrez C, Garcia C, Ridao C, Oliver JA, Richart C: Cardiac involvement in autosomaldominant polycystic kidney disease: a hypertensive heart disease. Clin Nephrol 2001;56:211-220.
8. Guay-Woodford LM: Murine models of polycystic kidney disease: Molecular and therapeutic insights. Am J Physiol 2003;285:F1034-1049.
9. Al-Nimri MA, Komers R, Oyama TT, Subramanya AR, Lindsley JN, Anderson S: Endothelial-derived vasoactive mediators in polycystic kidney disease. Kidney Int 2003;63:1776-1784.
10. Nauta J, Goedbloed MA, Herck HV, Hesselink DA, Visser P, Willemsen R, Dokkum RP, Wright CJ, Guay-Woodford LM: New rat model that phenotypically resembles autosomal recessive polycystic kidney disease. J Am Soc Nephrol 2000;11:2272-2284.
11. Braun C, Ludicke C, Rebsch W, Gretz N, van der Woude FJ, Rohmeiss P: Autoregulation of renal blood flow and pressure-dependent renin release in autosomal dominant polycystic kidney disease of rats. Nephrol Dial Transplant 1996;11(suppl 6):52-57.
12. Boulter C, Mulroy S, Webb S, Fleming S, Brindle K, Sandford R: Cardiovascular, skeletal, and renal defects in mice with a targeted disruption of the pkd1 gene. Proc Natl Acad Sci USA 2001;98:12174-12179.
13. Phillips JK, Rangan G, Hopwood D, McKitrick DJ: Characterisation of hypertension in a new model of PKD in rats. J Hypertens 2004;22:157S [Abstract].
14. Lantinga-van Leeuwen IS, Dauwerse JG, Baelde HJ, Leonhard WN, van de Wal A, Ward CJ, Verbeek S, Deruiter MC, Breuning MH, de Heer E, Peters DJ: Lowering of pkd1 expression is sufficient to cause polycystic kidney disease. Hum Mol Genet 2004;13:3069-3077.
15. Thomson RB, Mentone S, Kim R, Earle K, Delpire E, Somlo S, Aronson PS: Histopathological analysis of renal cystic epithelia in the pkd2ws25/-mouse model of adpkd. Am J Physiol 2003;285:F870-880.
16. Maunsbach AB, Marples D, Chin E, Ning G, Bondy C, Agre P, Nielsen S: Aquaporin-1 water channel expression in human kidney. J Am Soc Nephrol 1997;8:1-14.
17. Bachmann S, Metzger R, Bunnemann B: Tamm-horsfall protein-mRNA synthesis is localized to the thick ascending limb of Henle's loop in rat kidney. Histochemistry 1990;94:517-523.
18. Kishore BK, Krane CM, Di Iulio D, Menon AG, Cacini W: Expression of renal aquaporins 1, 2, and 3 in a rat model of cisplatin-induced polyuria. Kidney Int 2000;58:701-711.
19. Menezes LF, Cai Y, Nagasawa Y, Silva AM, Watkins ML, Da Silva AM, Somlo S, Guay-Woodford LM, Germino GG, Onuchic LF: Polyductin, the pkhd1 gene product, comprises isoforms expressed in plasma membrane, primary cilium, and cytoplasm. Kidney Int 2004;66:1345-1355.
20. Rangan GK, Pippin JW, Couser WG: C5b-9 regulates peritubular myofibroblast accumulation in experimental focal segmental glomerulosclerosis. Kidney Int 2004;66:1838-1848.
21. Harris DC, Rangan GK: Retardation of kidney failure: applying principles to practice. Ann Acad Med Singapore 2005;34:16-23.
22. Igarashi P, Somlo S: Genetics and pathogenesis of polycystic kidney disease. J Am Soc Nephrol 2002;13:2384-2398.
23. Ward CJ, Hogan MC, Rossetti S, Walker D, Sneddon T, Wang X, Kubly V, Cunningham JM, Bacallao R, Ishibashi M, Milliner DS, Torres VE, Harris PC: The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat Genet 2002;30:259-269.
24. Harris PC, Rossetti S: Molecular genetics of autosomal recessive polycystic kidney disease. Mol Genet Metab 2004;81:75-85.
25. Lager DJ, Qian Q, Bengal RJ, Ishibashi M, Torres VE: The pck rat: A new model that resembles human autosomal dominant polycystic kidney and liver disease. Kidney Int 2001;59:126-136.
26. Ricker JL, Gattone VH 2nd, Calvet JP, Rankin CA: Development of autosomal recessive polycystic kidney disease in Balb/ccpk/cpk mice. J Am Soc Nephrol 2000;11:1837-1847.
27. Devuyst O, Burrow CR, Smith BL, Agre P, Knepper MA, Wilson PD: Expression of aquaporins-1 and -2 during nephrogenesis and in autosomal dominant polycystic kidney disease. Am J Physiol 1996;271:F169-183.
28. Bissler JJ, Dixon BP: A mechanistic approach to inherited polycystic kidney disease. Pediatr Nephrol 2005;20:558-566.
29. Inage Z, Kikkawa Y, Minato M, Owada M, Kitagawa T, Ohno K, Kondo K, Ueda Y, Iidaka K: Autosomal recessive polycystic kidney in rats. Nephron 1991;59:637-640.
30. Cowley BD Jr, Gudapaty S, Kraybill AL, Barash BD, Harding MA, Calvet JP, Gattone VH 2nd: Autosomal-dominant polycystic kidney disease in the rat. Kidney Int 1993;43:522-534.
31. Gattone VH 2nd, Tourkow BA, Trambaugh CM, Yu AC, Whelan S, Phillips CL, Harris PC, Peterson RG: Development of multiorgan pathology in the wpk rat model of polycystic kidney disease. Anat Rec A Discov Mol Cell Evol Biol 2004;277:384-395.
32. Kranzlin B, Schieren G, Gretz N: Azotemia and extrarenal manifestations in old female Han:Sprd (cy/+) rats. Kidney Int 1997;51:1160-1169.
33. Gabow PA, Johnson AM, Kaehny WD, Kimberling WJ, Lezotte DC, Duley IT, Jones RH: Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int 1992;41:1311-1319.
34. Gretz N, Ceccherini I, Kranzlin B, Kloting I, Devoto M, Rohmeiss P, Hocher B, Waldherr R, Romeo G: Gender-dependent disease severity in autosomal polycystic kidney disease of rats. Kidney Int 1995;48:496-500.
35. Stringer KD, Komers R, Osman SA, Oyama TT, Lindsley JN, Anderson S: Gender hormones and the progression of experimental polycystic kidney disease. Kidney Int 2005;68:1729-1739.
36. Gonzalo A, Gallego A, Rivera M, Orte L, Ortuno J: Influence of hypertension on early renal insufficiency in autosomal dominant polycystic kidney disease. Nephron 1996;72:225-230.
37. Zerres K, Rudnik-Schoneborn S, Senderek J, Eggermann T, Bergmann C: Autosomal recessive polycystic kidney disease (ARPKD). J Nephrol 2003;16:453-458.
38. Chapman AB, Johnson AM, Rainguet S, Hossack K, Gabow P, Schrier RW: Left ventricular hypertrophy in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1997;8:1292-1297.
39. Schrier R, McFann K, Johnson A, Chapman A, Edelstein C, Brosnahan G, Ecder T, Tison L: Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. J Am Soc Nephrol 2002;13:1733-1739.
40. Fall PJ, Prisant LM: Polycystic kidney disease. J Clin Hypertens 2005;7:617-625.
41. Valvo E, Gammaro L, Tessitore N, Panzetta G, Lupo A, Loschiavo C, Oldrizzi L, Fabris A, Rugiu C, Ortalda V, et al.: Hypertension of polycystic kidney disease: Mechanisms and hemodynamic alterations. Am J Nephrol 1985;5:176-181.
42. Danielsen H, Nielsen AH, Pedersen EB, Herlevsen P, Kornerup HJ, Posborg V: Exaggerated natriuresis in adult polycystic kidney disease. Acta Med Scand 1986;219:59-66.
43. Doulton TW, Saggar-Malik AK, He FJ, Carney C, Markandu ND, Sagnella GA, MacGregor GA: The effect of sodium and angiotensin-converting enzyme inhibition on the classic circulating renin-angiotensin system in autosomal-dominant polycystic kidney disease patients. J Hypertens 2006;24:939-945.
44. Sorensen SS, Glud TK, Sorensen PJ, Amdisen A, Pedersen EB: Change in renal tubular sodium and water handling during progression of polycystic kidney disease: relationship to atrial natriuretic peptide. Nephrol Dial Transplant 1990;5:247-257.
45. Hackenthal E, Paul M, Ganten D, Taugner R: Morphology, physiology, and molecular biology of renin secretion Physiol Rev 1990;70.
46. Skott O: Renin. Am J Physiol Regul Integr Comp Physiol 2002;282:R937-R939.
47. Harrap SB, Dominiczak AF, Fraser R, Lever AF, Morton JJ, Foy CJ, Watt GC: Plasma angiotensin II, predisposition to hypertension, and left ventricular size in healthy young adults. Circulation 1996;93:1148-1154.
48. Thananopavarn C, Golub MS, Eggena P, Barrett JD, Sambhi MP: Angiotensin II, plasma renin and sodium depletion as determinants of blood pressure response to saralasin in essential hypertension. Circulation 1980;61:920-924.
49. Kosunen KJ, Pakarinen AJ, Kuoppasalmi K, Adlercreutz H: Plasma renin activity, angiotensin II, and aldosterone during intense heat stress. J Appl Physiol 1976;41:323-327.
50. Ayers CR, Katholi RE, Vaughan EDJ, Carey RM, Kimbrough HMJ, Yancey MR, Morton CL: Intrarenal renin-angiotensin-sodium interdependent mechanism controlling postclamp renal artery pressure and renin release in the conscious dog with chronic one-kidney Goldblatt hypertension. Circ Res 1977;40:238-242.
51. Liard JF, Cowley AWJ, McCaa RE, Guyton AC: Renin, aldosterone, body fluid volumes, and the baroreceptor reflex in the development and reversal of goldblatt hypertension in conscious dogs. Circ Res 1974;34:549-560.
52. Dzau VJ, Colucci WS, Hollenberg NK, Williams GH: Relation of the renin-angiotensinaldosterone system to clinical state in congestive heart failure. Circulation 1981;63:645-651.
53. Watkins LJ, Burton JA, Haber E, Cant JR, Smith FW, Barger AC: The renin-angiotensin-aldosterone system in congestive failure in conscious dogs. J Clin Invest 1976;57:1606-1617.
54. Pedersen KM, Pedersen HD, Haggstrom J, Koch J, Ersboll AK: Increased mean arterial pressure and aldosterone-to-renin ratio in Persian cats with polycystic kidney disease. J Vet Intern Med 2003;17:21-27.
55. Hollenberg NK: Aldosterone in the development and progression of renal injury. Kidney Int 2004;66:1-9.
56. Cerasola G, Vecchi M, Mule G, Cottone S, Mangano MT, Andronico G, Contorno A, Parrino I, Renda F, Pavone G: Sympathetic activity and blood pressure pattern in autosomal dominant polycystic kidney disease hypertensives. Am J Nephrol 1998;18:391-398.
57. Roysommuti S, Mozaffari MS, Wyss JM: Insulin-exacerbated hypertension in captopril-treated spontaneously hypertensive rats: role of sympathoexcitation. Can J Physiol Pharmacol 2003;81:1036-1041.
58. Bergamaschi C, Campos RR, Schor N, Lopes OU: Role of the rostral ventrolateral medulla in maintenance of blood pressure in rats with Goldblatt hypertension. Hypertension 1995;26:1117-1120.
59. Korner PI, Angus JA: Structural determinants of vascular resistance properties in hypertension: haemodynamic and model analysis. J Vasc Res 1992;29:293-312.
60. McKinley MJ, Allen AM, Burns P, Colvill LM, Oldfield BJ: Interaction of circulating hormones with the brain: the roles of the subfornical organ and the organum vasculosum of the lamina terminalis. Clin Exp Pharmacol Physiol Suppl 1998;25:S61-67.
61. Fitch GK, Weiss ML: Activation of renal afferent pathways following furosemide treatment. II. Effect of angiotensin blockade. Brain Res 2000;861:377-389.
62. Converse RL, Jacobsen TN, Toto RD, Jost CMT, Cosentino F, Tarazi F, Victor GG: Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992;327:1912-1918.
63. Ciriello J, de Oliveira CV: Renal afferents and hypertension. Curr Hypertens Rep 2002;4:136-142.
64. Ye S, Zhong H, Yanamadala V, Campese VM: Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens 2002;15:717-724.
65. Campese VM, Kogosov E: Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995;25:878-882.
66. Tao Y, Kim J, Schrier RW, Edelstein CL: Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 2005;16:46-51.